Harel Insurance Investments & Financial Services’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.76M | Buy |
2,822
+718
| +34% | +$489K | 0.01% | 177 |
|
|
2026
Q1 | $1.63M | Sell |
2,104
-32
| -1% | -$24.5K | 0.01% | 146 |
|
|
2025
Q4 | $1.65M | Buy |
2,136
+164
| +8% | +$111K | 0.01% | 155 |
|
|
2025
Q3 | $1.11M | Buy |
1,972
+834
| +73% | +$472K | 0.01% | 189 |
|
|
2025
Q2 | $597K | Buy |
1,138
+495
| +77% | +$276K | 0.01% | 204 |
|
|
2025
Q1 | $408K | Buy |
643
+8
| +1% | +$5.5K | 0.01% | 223 |
|
|
2024
Q4 | $452K | Sell |
635
-24
| -4% | -$20.1K | 0.01% | 157 |
|
|
2024
Q3 | $693K | Buy |
659
+266
| +68% | +$296K | 0.01% | 156 |
|
|
2024
Q2 | $413K | Sell |
393
-289
| -42% | -$280K | 0.01% | 193 |
|
|
2024
Q1 | $656K | Buy |
682
+362
| +113% | +$344K | 0.01% | 154 |
|
|
2023
Q4 | $281K | Sell |
320
-403
| -56% | -$332K | ﹤0.01% | 250 |
|
|
2023
Q3 | $598K | Buy |
723
+372
| +106% | +$292K | 0.01% | 180 |
|
|
2023
Q2 | $252K | Sell |
351
-3,294
| -90% | -$2.54M | 0.01% | 286 |
|
|
2023
Q1 | $2.96M | Sell |
3,645
-2,338
| -39% | -$1.76M | 0.06% | 116 |
|
|
2022
Q4 | $4.3M | Buy |
5,983
+3,268
| +120% | +$2.41M | 0.09% | 95 |
|
|
2022
Q3 | $1.88M | Buy |
2,715
+764
| +39% | +$481K | 0.05% | 139 |
|
|
2022
Q2 | $1.15M | Buy |
1,951
+1,891
| +3,152% | +$1.23M | 0.02% | 176 |
|
|
2022
Q1 | $42K | Sell |
60
-2,418
| -98% | -$1.53M | ﹤0.01% | 536 |
|
|
2021
Q4 | $1.59M | Buy |
2,478
+2,106
| +566% | +$1.29M | 0.03% | 139 |
|
|
2021
Q3 | $225K | Sell |
372
-1,861
| -83% | -$1.16M | 0.01% | 356 |
|
|
2021
Q2 | $4.07M | Buy |
2,233
+1,107
| +98% | +$561K | 0.09% | 112 |
|
|
2021
Q1 | $1.78M | Sell |
1,126
-512
| -31% | -$249K | 0.03% | 262 |
|
|
2020
Q4 | $2.37M | Buy |
1,638
+131
| +9% | +$70.7K | 0.06% | 162 |
|
|
2020
Q3 | $844K | Buy |
+1,507
| New | +$914K | 0.03% | 139 |
|
|
2020
Q2 | – | Sell |
-643
| Closed | -$314K | – | 570 |
|
|
2020
Q1 | $314K | Buy |
643
+207
| +47% | +$85.4K | 0.01% | 136 |
|
|
2019
Q4 | $164K | Buy |
436
+293
| +205% | +$98.6K | 0.01% | 222 |
|
|
2019
Q3 | $39K | Hold |
143
| – | – | ﹤0.01% | 326 |
|
|
2019
Q2 | $45K | Buy |
143
+73
| +104% | +$24.3K | ﹤0.01% | 326 |
|
|
2019
Q1 | $29K | Buy |
+70
| New | +$28.8K | ﹤0.01% | 326 |
|
|
2017
Q1 | – | Sell |
-2
| Closed | -$1K | – | 471 |
|
|
2016
Q4 | $1K | Sell |
2
-80
| -98% | -$30.4K | ﹤0.01% | 364 |
|
|
2016
Q3 | $33K | Hold |
82
| – | – | ﹤0.01% | 254 |
|
|
2016
Q2 | $29K | Buy |
82
+2
| +3% | +$770 | ﹤0.01% | 413 |
|
|
2016
Q1 | $29K | Sell |
80
-60
| -43% | -$24.7K | ﹤0.01% | 247 |
|
|
2015
Q4 | $76K | Buy |
+140
| New | +$75.9K | 0.01% | 170 |
|
Other funds holding REGN
N
Harel Insurance Investments & Financial Services's REGN Position: Q2 2026 in Review
Harel Insurance Investments & Financial Services increased its Regeneron Pharmaceuticals (REGN) stake by 34% in Q2 2026, buying an estimated $489K and bringing the position to 2,822 shares worth $1.76M. The position accounts for 0.01% of the portfolio, ranked #177.
Harel Insurance Investments & Financial Services first reported a position in REGN in Q4 2015 and has held it in 34 quarters since. The position peaked at $4.3M in Q4 2022. 955 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Harel Insurance Investments & Financial Services held 2,822 shares of Regeneron Pharmaceuticals worth $1.76M as of Q2 2026.
- Harel Insurance Investments & Financial Services bought 718 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $489K.
- Regeneron Pharmaceuticals made up 0.01% of Harel Insurance Investments & Financial Services's portfolio in Q2 2026, its #177 holding.
- Harel Insurance Investments & Financial Services first reported a position in Regeneron Pharmaceuticals in Q4 2015 and has held it in 34 quarters since.
- Harel Insurance Investments & Financial Services's Regeneron Pharmaceuticals position peaked at $4.3M in Q4 2022.
- 955 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Harel Insurance Investments & Financial Services's 13F filing for Q2 2026, filed 29 Jul 2026.